• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza viruses

tetano

Editor, Senior Moderator
Nat Commun


. 2026 Mar 2.
doi: 10.1038/s41467-026-70036-8. Online ahead of print.
Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza viruses

Saya Moriyama[SUP] #[/SUP][SUP] 1 [/SUP], Julia di Iulio[SUP] #[/SUP][SUP] 2 [/SUP], Fabrizia Zatta[SUP] #[/SUP][SUP] 3 [/SUP], Kevin Hauser[SUP] #[/SUP][SUP] 2 [/SUP], Hideki Asanuma[SUP] 4 [/SUP], Hector E Muñoz[SUP] 2 [/SUP], John M Errico[SUP] 2 [/SUP], Yu Adachi[SUP] 1 [/SUP], Ha V Dang[SUP] 2 [/SUP], Nadine Czudnochowski[SUP] 2 [/SUP], Eita Sasaki[SUP] 1 4 [/SUP], Alex Chen[SUP] 2 [/SUP], Yi-Pei Chen[SUP] 2 [/SUP], Ryutaro Kotaki[SUP] 1 [/SUP], Alessia Peter[SUP] 3 [/SUP], Eneida Vetti[SUP] 3 [/SUP], Taishi Onodera[SUP] 1 [/SUP], M Cyrus Maher[SUP] 2 [/SUP], Laura E Rosen[SUP] 2 [/SUP], Masayuki Shirakura[SUP] 1 [/SUP], Gyorgy Snell[SUP] 2 [/SUP], Hideki Hasegawa[SUP] 4 5 [/SUP], Yoshimasa Takahashi[SUP] 6 7 [/SUP], Davide Corti[SUP] 8 [/SUP], Matteo Samuele Pizzuto[SUP] 9 [/SUP]


Affiliations
Abstract

For nearly 30 years, Goose/Guangdong-derived highly pathogenic avian influenza H5N1 viruses have posed significant risks to economic stability, food security, and public health. Virus evolution has resulted in various clades, including the panzootic subclade 2.3.4.4b, recognized for its pandemic potential. Here we present the potent in vitro activity of FNI9, a pan-influenza NA-inhibiting monoclonal antibody, against a range of pseudoparticles with NA spanning decades of H5N1 virus evolution. FNI9 also shows strong prophylactic protection in female mice against lethal challenges with H5N1 from clade 1 and 2.3.4.4b. Cryo-EM and molecular dynamics analysis reveal that FNI9 binds to 7 highly conserved H5N1 NA residues (R118, E119, D151, E228, E278, R293, and R368). In silico evolutionary escape profiling and machine learning predict low escapability, high fitness costs, and minimal spread likelihood for viral mutations that evade FNI9 binding. These findings support FNI9 broad protection and underscore the NA role in future influenza vaccine design.


 
Back
Top